Ligand to invest up to $47M in AveCell for royalty stake
Ligand Pharmaceuticals agreed to finance two clinical-stage cell therapy candidates with up to $47 million, securing a royalty potential mid single-digit to low double-digit royalties on global sales.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed